NO333712B1 - Orodispersibel farmasoytisk sammensetning omfattende agomelatin - Google Patents
Orodispersibel farmasoytisk sammensetning omfattende agomelatin Download PDFInfo
- Publication number
- NO333712B1 NO333712B1 NO20043441A NO20043441A NO333712B1 NO 333712 B1 NO333712 B1 NO 333712B1 NO 20043441 A NO20043441 A NO 20043441A NO 20043441 A NO20043441 A NO 20043441A NO 333712 B1 NO333712 B1 NO 333712B1
- Authority
- NO
- Norway
- Prior art keywords
- agomelatine
- pharmaceutical composition
- tablets
- orodispersible
- tablet
- Prior art date
Links
- 229960002629 agomelatine Drugs 0.000 title claims abstract description 26
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 11
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 7
- 239000008101 lactose Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000007907 direct compression Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 230000027288 circadian rhythm Effects 0.000 claims description 2
- 230000003831 deregulation Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001193 melatoninergic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0200792A FR2834890B1 (fr) | 2002-01-23 | 2002-01-23 | Composition pharmaceutique orodispersible d'agomelatine |
| PCT/FR2003/000197 WO2003061644A1 (fr) | 2002-01-23 | 2003-01-22 | Composition pharmaceutique orodispersible d’agomelatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043441L NO20043441L (no) | 2004-08-18 |
| NO333712B1 true NO333712B1 (no) | 2013-09-02 |
Family
ID=27589556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043441A NO333712B1 (no) | 2002-01-23 | 2004-08-18 | Orodispersibel farmasoytisk sammensetning omfattende agomelatin |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20050131071A1 (ja) |
| EP (1) | EP1467724B1 (ja) |
| JP (2) | JP4335011B2 (ja) |
| KR (1) | KR100605798B1 (ja) |
| CN (1) | CN1287780C (ja) |
| AR (1) | AR038207A1 (ja) |
| AT (1) | ATE324882T1 (ja) |
| AU (1) | AU2003220786B2 (ja) |
| BR (1) | BRPI0307072B1 (ja) |
| CA (1) | CA2473201C (ja) |
| CY (1) | CY1105415T1 (ja) |
| DE (1) | DE60304993T2 (ja) |
| DK (1) | DK1467724T3 (ja) |
| EA (1) | EA007299B1 (ja) |
| ES (1) | ES2262999T3 (ja) |
| FR (1) | FR2834890B1 (ja) |
| GE (1) | GEP20063818B (ja) |
| HK (1) | HK1076742A1 (ja) |
| MA (1) | MA27101A1 (ja) |
| MX (1) | MXPA04007198A (ja) |
| NO (1) | NO333712B1 (ja) |
| NZ (1) | NZ533843A (ja) |
| PL (1) | PL204937B1 (ja) |
| PT (1) | PT1467724E (ja) |
| SI (1) | SI1467724T1 (ja) |
| UA (1) | UA77752C2 (ja) |
| WO (1) | WO2003061644A1 (ja) |
| ZA (1) | ZA200405153B (ja) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2834889B1 (fr) * | 2002-01-18 | 2004-04-02 | Roquette Freres | Forme pharmaceutique solide orodispersible |
| US20030228370A1 (en) * | 2002-06-11 | 2003-12-11 | Michel Serpelloni | Orodispersible solid pharmaceutical form |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| FR2884714B1 (fr) * | 2005-04-20 | 2011-05-06 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires |
| FR2890564B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
| FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
| FR2894475B1 (fr) * | 2005-12-14 | 2008-05-16 | Servier Lab | Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine |
| CN101394837A (zh) * | 2006-03-06 | 2009-03-25 | 特瓦制药工业有限公司 | 折替米贝组合物 |
| CN101206200B (zh) * | 2006-12-19 | 2011-12-28 | 北京德众万全药物技术开发有限公司 | 一种分离分析阿戈美拉汀中间体及其终产品的hplc方法 |
| US7608737B2 (en) * | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
| EP2359813A1 (en) * | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| CN101836966A (zh) * | 2010-05-27 | 2010-09-22 | 北京万全阳光医药科技有限公司 | 一种含有阿戈美拉汀的口腔崩解片 |
| CN102579415B (zh) * | 2011-01-14 | 2014-11-05 | 成都康弘药业集团股份有限公司 | 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物 |
| US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| JP5600747B2 (ja) | 2011-01-17 | 2014-10-01 | 武田薬品工業株式会社 | 口腔内分散性製剤 |
| WO2012130837A1 (en) * | 2011-03-28 | 2012-10-04 | Ratiopharm Gmbh | Solid agomelatine in non-crystalline form |
| FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2562151A1 (en) * | 2011-08-25 | 2013-02-27 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of agomelatine and its intermediates |
| WO2013054582A1 (en) | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| CN103169669B (zh) * | 2011-12-26 | 2015-06-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 阿戈美拉汀包衣微丸以及可在口中分散的药物组合物 |
| CA2877410A1 (en) | 2012-07-16 | 2014-01-23 | Ratiopharm Gmbh | Complex of agomelatine and cyclodextrin |
| CN102988315B (zh) * | 2012-09-28 | 2017-11-17 | 浙江华海药业股份有限公司 | 阿戈美拉汀固体制剂的制备方法 |
| FR3001894A1 (fr) * | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| PL2810656T3 (pl) | 2013-06-06 | 2018-01-31 | Zentiva Ks | Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów |
| CN103816129B (zh) * | 2014-02-27 | 2020-04-28 | 浙江华海药业股份有限公司 | 阿戈美拉汀口崩片 |
| CN104586797A (zh) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | 阿戈美拉汀分散片及其制备方法 |
| CN106333929A (zh) * | 2016-09-24 | 2017-01-18 | 万特制药(海南)有限公司 | 一种含有阿戈美拉汀的分散片及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3505433A1 (de) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | Direkttablettierhilfsmittel |
| DE3506276C1 (de) * | 1985-02-22 | 1986-04-24 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Direkttablettiermittel |
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2710265B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| AU699715B2 (en) * | 1994-01-31 | 1998-12-10 | Astellas Pharma Inc. | Intrabuccally dissolving compressed moldings and production process thereof |
| DK0906089T3 (da) * | 1996-05-13 | 2003-12-08 | Novartis Consumer Health Sa | Mundafgivelsessystem |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| JP2002505269A (ja) * | 1998-03-06 | 2002-02-19 | エウランド インターナショナル ソシエタ ペル アチオニ | 急速崩壊錠剤 |
| JP2000273039A (ja) * | 1999-01-20 | 2000-10-03 | Taisho Pharmaceut Co Ltd | 口腔内崩壊性組成物 |
| ES2292414T3 (es) * | 2000-07-27 | 2008-03-16 | Roquette Freres | Granulos a base de almidon y de lactosa. |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| FR2834889B1 (fr) * | 2002-01-18 | 2004-04-02 | Roquette Freres | Forme pharmaceutique solide orodispersible |
-
2002
- 2002-01-23 FR FR0200792A patent/FR2834890B1/fr not_active Expired - Fee Related
-
2003
- 2003-01-22 US US10/502,593 patent/US20050131071A1/en not_active Abandoned
- 2003-01-22 KR KR1020047011351A patent/KR100605798B1/ko not_active IP Right Cessation
- 2003-01-22 AR ARP030100178A patent/AR038207A1/es unknown
- 2003-01-22 SI SI200330266T patent/SI1467724T1/sl unknown
- 2003-01-22 JP JP2003561589A patent/JP4335011B2/ja not_active Expired - Fee Related
- 2003-01-22 AT AT03731733T patent/ATE324882T1/de active
- 2003-01-22 CN CNB038027100A patent/CN1287780C/zh not_active Expired - Fee Related
- 2003-01-22 CA CA2473201A patent/CA2473201C/fr not_active Expired - Fee Related
- 2003-01-22 GE GE5625A patent/GEP20063818B/en unknown
- 2003-01-22 EA EA200400928A patent/EA007299B1/ru not_active IP Right Cessation
- 2003-01-22 ES ES03731733T patent/ES2262999T3/es not_active Expired - Lifetime
- 2003-01-22 MX MXPA04007198A patent/MXPA04007198A/es active IP Right Grant
- 2003-01-22 DE DE60304993T patent/DE60304993T2/de not_active Expired - Lifetime
- 2003-01-22 WO PCT/FR2003/000197 patent/WO2003061644A1/fr active IP Right Grant
- 2003-01-22 EP EP03731733A patent/EP1467724B1/fr not_active Expired - Lifetime
- 2003-01-22 NZ NZ533843A patent/NZ533843A/en not_active IP Right Cessation
- 2003-01-22 BR BRPI0307072A patent/BRPI0307072B1/pt not_active IP Right Cessation
- 2003-01-22 PT PT03731733T patent/PT1467724E/pt unknown
- 2003-01-22 PL PL370160A patent/PL204937B1/pl unknown
- 2003-01-22 UA UA20040806965A patent/UA77752C2/uk unknown
- 2003-01-22 AU AU2003220786A patent/AU2003220786B2/en not_active Ceased
- 2003-01-22 DK DK03731733T patent/DK1467724T3/da active
-
2004
- 2004-06-28 ZA ZA2004/05153A patent/ZA200405153B/en unknown
- 2004-07-12 MA MA27775A patent/MA27101A1/fr unknown
- 2004-08-18 NO NO20043441A patent/NO333712B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 HK HK05108935A patent/HK1076742A1/xx not_active IP Right Cessation
-
2006
- 2006-06-30 CY CY20061100898T patent/CY1105415T1/el unknown
-
2009
- 2009-01-20 JP JP2009010024A patent/JP2009137994A/ja active Pending
-
2010
- 2010-06-22 US US12/803,250 patent/US20100260840A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333712B1 (no) | Orodispersibel farmasoytisk sammensetning omfattende agomelatin | |
| US20100267693A1 (en) | Orodispersible pharmaceutical composition of ivabradine | |
| US20100267799A1 (en) | Orodispersible pharmaceutical composition of perindopril | |
| AU2004258713B2 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| AU2003214326B2 (en) | Orally dispersible pharmaceutical piribedil composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |